清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Neoadjuvant immunochemotherapy with adebrelimab combined with the TP regimen for locally advanced OSCC: early results of a single-arm phase II clinical trial

医学 临床终点 内科学 卡铂 不利影响 中止 养生 完全响应 人口 临床研究阶段 临床试验 实体瘤疗效评价标准 病态的 外科 肿瘤科 胃肠病学 化疗 顺铂 环境卫生
作者
Yilin He,Yuepeng Wang,Junhong Guo,Ziqin Kang,Zuozhen Wen,Yongkang Cai,Songling Fang,Wenhao Li,Xiumei Zhuang,Zixian Huang,Yan Wang,Zhiquan Huang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
标识
DOI:10.1097/js9.0000000000003023
摘要

Background: This study aimed to investigate the efficacy of a PD-L1 inhibitor combined with chemotherapy in the treatment of locally advanced OSCC. Materials and Methods: This study was designed as a single-arm phase II trial, and a total of 30 patients were enrolled. All patients were pathologically confirmed to have head and neck squamous cell carcinoma. Patients received paclitaxel, carboplatin, and adebrelimab every 3 weeks as a treatment cycle, followed by surgery after three cycles of treatment. The primary endpoint was the postoperative pathological complete response (PCR) rate. The secondary endpoints included the objective response rate (ORR), major pathological response (MPR) rate, 2-year disease-free survival (DFS) rate, and 2-year and 5-year overall survival (OS) rates. This study was conducted without using artificial intelligence (AI) tools in accordance with the TITAN Guidelines 2025. Results: Among the 30 patients, 28 completed the full three cycles of immunochemotherapy, with an objective response rate (ORR) of 60.7%. One patient dropped out, and one patient (3.3%) experienced grade 3–4 adverse reactions, leading to discontinuation after the first cycle. In the per-protocol population, 10 patients (35.7%) achieved a PCR in both the primary lesion and lymph nodes, whereas 18 patients (64.3%), including those with a PCR, achieved a major pathological response (MPR). Additionally, 20 patients (71.4%) achieved clinical to pathological downstaging. Common adverse reactions included alopecia (30; 100%), fatigue (7; 23.3%), anemia (24; 80%), hyperthyroidism (2; 6.7%), and pruritus (5; 16.7%). Conclusions: Preoperative neoadjuvant immunochemotherapy effectively improved the PCR rate in patients with locally advanced OSCC. PD-L1 inhibitors combined with chemotherapy have promising preliminary efficacy in patients with resectable locally advanced oral squamous cell carcinoma (OSCC). However, additional follow-up is needed to obtain more comprehensive survival data and further validate these initial observations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梅梅美美完成签到 ,获得积分10
3秒前
清爽的口红完成签到,获得积分10
8秒前
认真的狗发布了新的文献求助20
14秒前
虚幻唯雪完成签到,获得积分10
47秒前
我是老大的应助被LeoAllen849采纳,获得40
51秒前
nk完成签到 ,获得积分10
52秒前
56秒前
剁辣椒蒸鱼头完成签到 ,获得积分10
58秒前
冷酷紫烟完成签到,获得积分10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
科研通AI65的应助被海宁采纳,获得10
1分钟前
1分钟前
怕孤独的梦寒完成签到,获得积分10
1分钟前
风中黎昕完成签到 ,获得积分10
1分钟前
海宁发布了新的文献求助10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
shoemaker完成签到,获得积分10
2分钟前
夏纪完成签到 ,获得积分10
2分钟前
柔弱的水风完成签到,获得积分10
2分钟前
u404711发布了新的文献求助10
2分钟前
舒心鞋垫完成签到,获得积分10
2分钟前
快乐舒完成签到 ,获得积分10
3分钟前
n01W97的应助被科研通管家采纳,获得40
3分钟前
无限的水香完成签到,获得积分10
3分钟前
朴实水云完成签到,获得积分10
3分钟前
Cakoibao的应助被dianeil采纳,获得10
3分钟前
YYM完成签到 ,获得积分10
3分钟前
3分钟前
激情的盼晴完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
yanweihome完成签到 ,获得积分10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185392
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782811
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481272